Currently, there are 64.39M common shares owned by the public and among those 59.08M shares have been available to trade.
The company’s stock has a 5-day price change of 196.97% and 125.81% over the past three months. GLYC shares are trading -79.24% year to date (YTD), with the 12-month market performance down to -57.39% lower. It has a 12-month low price of $0.14 and touched a high of $3.53 over the same period. GLYC has an average intraday trading volume of 1.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 179.76%, 185.07%, and -58.86% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of GlycoMimetics Inc (NASDAQ: GLYC) shares accounts for 35.62% of the company’s 64.39M shares outstanding.
It has a market capitalization of $31.60M and a beta (3y monthly) value of 2.04. The earnings-per-share (ttm) stands at -$0.61. Price movements for the stock have been influenced by the stock’s volatility, which stands at 29.76% over the week and 12.57% over the month.
Analysts forecast that GlycoMimetics Inc (GLYC) will achieve an EPS of -0.11 for the current quarter, -0.07 for the next quarter and -0.09 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.11 while analysts give the company a high EPS estimate of -0.11. Comparatively, EPS for the current quarter was -0.14 a year ago. Earnings per share for the fiscal year are expected to increase by 12.93%, and 82.18% over the next financial year.
CapitalOne coverage for the GlycoMimetics Inc (GLYC) stock in a research note released on December 22, 2023 offered a Overweight rating with a price target of $12. Jefferies was of a view on November 12, 2021 that the stock is Buy, while ROTH Capital gave the stock Buy rating on November 14, 2019, issuing a price target of $12. SunTrust on their part issued Hold rating on August 05, 2019.
